L.P. Ra Capital Management Acquires Septerna Shares
L.P. Ra Capital Management purchased 15,000 shares of Septerna, Inc. on June 26, 2026.
Key Points
- L.P. Ra Capital Management bought 15,000 shares of Septerna, Inc. on June 26, 2026, with the stock trading near $34.75 on Wednesday.
- Septerna, Inc. is a biotechnology company with a market cap of about $1.68 billion and a 52-week high of $37.99.
- Analysts maintain a strong buy consensus for Septerna, with Raymond James setting a $53 price target on June 8, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
L.P. Ra Capital Management made a move to acquire 15,000 shares of Septerna, Inc. (NasdaqGM: SEPN) on June 26, 2026. This insider transaction wasn't part of a pre-planned trading program. As of Wednesday, Septerna's stock was trading near $34.75.
Insider Buying and Selling at Septerna, Inc.
On June 26, 2026, L.P. Ra Capital Management purchased 15,000 shares of Septerna, Inc. This transaction wasn't made under a Rule 10b5-1 plan. On June 29, 2026, Samira Shaikhly, Chief People Officer, was involved in several transactions, including a planned sale of 2,178 shares at $35.18 and a purchase of the same amount at $6.81.
Septerna, Inc. Stock Down 12.2%
Shares of NasdaqGM:SEPN traded near $34.75 on Wednesday. Septerna, Inc. has a market capitalization of approximately $1.68 billion. The company's stock has a 52-week low of $10.3 and a high of $37.99. Its 50-day moving average is $28.91, and the 200-day moving average is $25.31. Septerna maintains a current ratio of 4.71 and a quick ratio of 4.63, with a debt-to-equity ratio of 6.10.
$SEPN stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 8, 2026, Raymond James maintained its buy rating on Septerna, Inc. with a price target of $53. Other firms, including JP Morgan and Wells Fargo, also maintain buy ratings with targets of $38 and $48, respectively. The consensus among analysts is a strong buy, with an average price target of $45.78 based on 9 analyst opinions.
About Septerna, Inc.
Septerna, Inc. is a biotechnology company based in South San Francisco, California. It is involved in discovering and developing small molecule products targeting G protein-coupled receptors (GPCRs) for treating various diseases. The company's pipeline includes treatments for hypoparathyroidism, chronic spontaneous urticaria, and thyroid-related diseases. Septerna collaborates with Novo Nordisk to develop therapies for metabolic diseases. Founded in 2019, the company operates under the leadership of CEO Dr. Jeffrey T. Finer.
Bottom Line
L.P. Ra Capital Management's recent purchase of Septerna shares highlights ongoing interest in the biotech firm. Septerna's innovative approach in the healthcare sector and strong analyst backing make it a company to watch. However, as with all 13F filings and insider transactions, these moves reflect past actions and may not indicate current positions.
Get Septerna, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SEPN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.